Physician profile
Brian Berberian
NPI 1861422586
$70,491.08
in general payments reported to CMS, 2019-2025
43 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $5,858 · 2021: $7,387 · 2022: $8,848 · 2023: $2,545 · 2024: $28K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $38K · Food and Beverage: $8,772 · Travel and Lodging: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $38,250.00 |
| Food and Beverage | $8,772.03 |
| Travel and Lodging | $396.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $40,176.11 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Qol Medical, LLC | $17,692.38 | 2019-2025 | Sucraid, Sucraid |
| Ambu INC. | $2,037.73 | 2020-2022 | |
| Boston Scientific Corporation | $1,358.31 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $993.52 | 2019-2025 | Xifaxan, Relistor, Plenvu |
| Abbvie INC. | $968.23 | 2020-2024 | Creon, Linzess, Viberzi |
| Olympus America INC. | $727.03 | 2022-2024 | Endoclot Phs |
| Ardelyx, INC. | $672.16 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $617.07 | 2021-2025 | |
| Steris Corporation | $571.48 | 2022 | |
| Novo Nordisk INC | $513.54 | 2019-2025 | Wegovy |
| Janssen Biotech, INC. | $507.40 | 2021-2025 | Tremfya, Stelara, Simponi |
| Evoke Pharma, INC. | $411.34 | 2021-2025 | Gimoti |
| Madrigal Pharmaceuticals | $407.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Medivators INC. | $376.89 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $301.18 | 2022-2023 | Hemospray |
| Medtronic, INC. | $261.67 | 2022-2023 | Bravo |
| E.R. Squibb & Sons, L.L.C. | $215.49 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $190.15 | 2021-2024 | Dificid |
| Shield Therapeutics INC | $165.07 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $134.22 | 2019-2023 | Entyvio |
| Glaxosmithkline, LLC. | $121.58 | 2020 | |
| Genzyme Corporation | $120.70 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $119.37 | 2024-2025 | Voquezna |
| Relievant Medsystems, INC. | $118.23 | 2022 | |
| Redhill Biopharma INC. | $108.28 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $77.76 | 2021 | |
| Astellas Pharma US INC | $64.96 | 2019 | |
| Celgene Corporation | $56.49 | 2021-2024 | Zeposia |
| Mindray Ds USA, INC. | $53.44 | 2025 | Na Electrode,Indirect,International, Patient Monitor |
| Regeneron Healthcare Solutions, INC. | $48.88 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $41.90 | 2021-2022 | |
| Echosens North America, INC. | $38.71 | 2022-2023 | Fibroscan |
| Allergan, INC. | $37.86 | 2019 | |
| Lilly USA, LLC | $34.42 | 2025 | Zepbound |
| Capsovision, INC. | $31.02 | 2023-2024 | Capsocam Plus |
| Currax Pharmaceuticals LLC | $27.83 | 2021 | |
| Exact Sciences Corporation | $24.35 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $15.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.75 | 2023 | Ocaliva |
| Bausch Health US, LLC | $13.64 | 2019 | |
| Amarin Pharma, INC. | $11.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Berberian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.